title: Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma.
abstract: Patients with diffuse large cell lymphoma may achieve complete remission (CR) after chemotherapy, and the time to reach CR may be predictive of treatment outcome. Partial remission, or recurrence from CR, is associated with poor survival. Gallium-67 imaging has proven to be useful in evaluating lymphoma patients. In tumor models, this radiotracer is an indicator of tumor viability. Gallium-67 uptake is seen only in avid and viable lymphoma tissue, not in fibrotic or necrotic tissue. In this study, we prospectively assessed the ability of this radiotracer to define residual disease. In addition, we evaluated the possibility of predicting the clinical outcome in patients with diffuse cell lymphoma on the basis of scan positivity during chemotherapy.
  
  
  METHODS
  Thirty-three consecutive patients with histologically proven diffuse large cell lymphoma were investigated with 67Ga scintigraphy 48-72 hr after injection of 185-259 MBq 67Ga-citrate for staging and during follow-up after four to six cycles of intensive chemotherapy. Patients were monitored for a mean of 56.0 mo (range 7-90 mo), and they were restaged using physical examination, CT and all necessary imaging modalities.
  
  
  RESULTS
  Patients were divided into two groups according to the positivity or negativity of 67Ga scan after four to six cycles of chemotherapy. Of the 33 patients studied, 14 (42.4%) showed persistent abnormal uptake of 67Ga-citrate after four to six cycles of chemotherapy. In this group, 9 patients (64.2%) died of lymphoma at a mean of 24.3 mo from presentation with the diagnosis (range 7-71 mo). Four patients had no evidence of disease at an average of 71.7 mo after diagnosis, and 1 patient was considered to be in partial remission. In the second group of 19 67Ga-negative patients, after four to six cycles of chemotherapy, 4 died and 15 are alive and considered to be in CR. A statistical analysis of the association between 67Ga scan results after four to six cycles of chemotherapy and survival was performed using the log-rank test; there was a statistically significant association between scan results and survival (p=0.00125).
  
  
  CONCLUSIONS
  We conclude that 67Ga scintigraphy is an excellent predictor of residual tumor viability in lymphoma patients and that persistent positivity of the scan predicts poor outcome and may justify a change in treatment.
authors.affiliation: Nuclear Medicine Department, Ospedale Maggiore-IRCCS, Milan, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Gasparini
authors.forename: E
authors.initials: E
authors.lastname: Bombardieri
authors.forename: M
authors.initials: M
authors.lastname: Castellani
authors.forename: C
authors.initials: C
authors.lastname: Tondini
authors.forename: L
authors.initials: L
authors.lastname: Maffioli
authors.forename: L
authors.initials: L
authors.lastname: Devizzi
authors.forename: P
authors.initials: P
authors.lastname: Gerundini
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002951:Citrates; D005260:Female; D005708:Gallium; D005710:Gallium Radioisotopes; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis
chemical_list: D002951:Citrates; D005710:Gallium Radioisotopes; D019275:Radiopharmaceuticals; D005708:Gallium; C103850:gallium citrate